Agenus (AGEN) reported second quarter 2026 revenue of $34.5 million, compared with $25.7 million a year earlier, as it advanced plans for the Phase 3 ROBBIN trial of botensilimab plus balstilimab in neoadjuvant microsatellite-stable colon cancer.
The company said it completed an oversubscribed $85 million private placement in July, with milestone-aligned warrants that could provide up to about $255 million in additional gross proceeds if fully exercised.
- Total revenue for the first six months of 2026 was $68.3 million, compared with $49.8 million a year earlier.
- Second quarter revenue included $6.4 million in pre-commercial BOT+BAL product revenue from authorized patient-access programs and $28.1 million in non-cash royalty revenue.
- ROBBIN is planned as a global randomized Phase 3 trial in about 850 previously untreated patients with high-risk Stage II and Stage III MSS colon cancer.
- Agenus said ROBBIN addresses about 38,000 newly diagnosed U.S. patients annually and an estimated annual U.S. sales opportunity of more than $7 billion.
- ROBBIN initiation and first patient dosing are expected in the first quarter of 2027.
$AGEN Hedge Fund Activity
We have seen 33 institutional investors add shares of $AGEN stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP added 541,403 shares (+368.8%) to their portfolio in Q1 2026, for an estimated $1,808,286
- ACADIAN ASSET MANAGEMENT LLC removed 407,437 shares (-65.5%) from their portfolio in Q1 2026, for an estimated $1,360,839
- CITADEL ADVISORS LLC removed 371,238 shares (-87.7%) from their portfolio in Q1 2026, for an estimated $1,239,934
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 277,912 shares (-99.8%) from their portfolio in Q1 2026, for an estimated $928,226
- RENAISSANCE TECHNOLOGIES LLC removed 257,900 shares (-47.4%) from their portfolio in Q1 2026, for an estimated $861,386
- MILLENNIUM MANAGEMENT LLC removed 181,930 shares (-80.7%) from their portfolio in Q1 2026, for an estimated $607,646
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 176,015 shares (-75.3%) from their portfolio in Q1 2026, for an estimated $587,890
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
